The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery

Abstract

BACKGROUND: Neoadjuvant chemotherapy (NAC) followed by surgery for resectable oesophageal or gastric cancer improves outcome when compared with surgery alone. However NAC has adverse effects. We assess here whether NAC adversely affects physical fitness and whether such an effect is associated with impaired survival following surgery.

METHODS: We prospectively studied 116 patients with oesophageal or gastric cancer to assess the effect of NAC on physical fitness, of whom 89 underwent cardiopulmonary exercise testing (CPET) before NAC and proceeded to surgery. 39 patients were tested after all cycles of NAC but prior to surgery. Physical fitness was assessed by measuring oxygen uptake (VO2 in ml kg(-1) min(-1)) at the estimated lactate threshold (?L) and at peak exercise (VO2 peak in ml kg(-1) min(-1)).

RESULTS: VO2 at ?L and at peak were significantly lower after NAC compared to pre-NAC values: VO2 at ?L 14.5 ± 3.8 (baseline) vs. 12.3 ± 3.0 (post-NAC) ml kg(-1) min(-1); p ? 0.001; VO2 peak 20.8 ± 6.0 vs. 18.3 ± 5.1 ml kg(-1) min(-1); p ? 0.001; absolute VO2 (ml min(-1)) at ?L and peak were also lower post-NAC; p ? 0.001. Decreased baseline VO2 at ?L and peak were associated with increased one year mortality in patients who completed a full course of NAC and had surgery; p = 0.014.

CONCLUSION: NAC before cancer surgery significantly reduced physical fitness in the overall cohort. Lower baseline fitness was associated with reduced one-year-survival in patients completing NAC and surgery, but not in patients who did not complete NAC. It is possible that in some patients the harms of NAC may outweigh the benefits.

Trials Registry Number: NCT01335555.

More information

Identifiers

ORCID for M.A. West: orcid.org/0000-0002-0345-5356

ORCID for M.P.W. Grocott: orcid.org/0000-0002-9484-7581

Catalogue record

Export record

Altmetrics